Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
223 0 |
SM ISO690:2012 HOUSSIAU, Frederic A., THANOU, Aikaterini, MAZUR, Minodora, RAMITERRE, Edgar B., GOMEZ MORA, Danny Alexis, MISTERSKA-SKORA, Maria Magdalena, PERICH-CAMPOS, Risto Alfredo, SMAKOTINA, Svetlana, CERPA CRUZ, Sergio, LOUZIR, Bassem, CROUGHS, Therese, TEE, Michael Lucas. IFN-α kinoid in systemic lupus erythematosus: Results from a phase IIb, randomised, placebo-controlled study. In: Annals of the Rheumatic Diseases, 2019, vol. 78, p. 0. ISSN -. DOI: https://doi.org/10.1136/annrheumdis-2019-216379 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Annals of the Rheumatic Diseases | |
Volumul 78 / 2019 / ISSN - /ISSNe 0003-4967 | |
|
|
DOI:https://doi.org/10.1136/annrheumdis-2019-216379 | |
Pag. 0-0 | |
Rezumat | |
Objective: To evaluate the efficacy and safety of the immunotherapeutic vaccine interferon-α kinoid (IFN-K) in a 36-week (W) phase IIb, randomised, double-blind, placebo (PBO)-controlled trial in adults with active systemic lupus erythematosus (SLE) despite standard of care. Methods: Patients with SLE (185) with moderate to severe disease activity and positive interferon (IFN) gene signature were randomised to receive IFN-K or PBO intramuscular injections (days 0, 7 and 28 and W12 and W24). Coprimary endpoints at W36 were neutralisation of IFN gene signature and the BILAG-Based Composite Lupus Assessment (BICLA) modified by mandatory corticosteroid (CS) tapering. Results: IFN-K induced neutralising anti-IFN-α2b serum antibodies in 91% of treated patients and reduced the IFN gene signature (p<0.0001). Modified BICLA responses at W36 did not statistically differ between IFN-K (41%) and PBO (34%). Trends on Systemic Lupus Erythematosus Responder Index-4, including steroid tapering at W36, favoured the IFN-K and became significant (p<0.05) in analyses restricted to patients who developed neutralising anti-IFN-α2b antibodies. Attainment of lupus low disease activity state (LLDAS) at W36 discriminated the two groups in favour of IFN-K (53% vs 30%, p=0.0022). A significant CS sparing effect of IFN-K was observed from W28 onwards, with a 24% prednisone daily dose reduction at W36 in IFN-K compared with PBO (p=0.0097). The safety profile of IFN-K was acceptable. Conclusions: IFN-K induced neutralising anti-IFN-α2b antibodies and significantly reduced the IFN gene signature with an acceptable safety profile. Although the clinical coprimary endpoint was not met, relevant secondary endpoints were achieved in the IFN-K group, including attainment of LLDAS and steroid tapering. Trial registration number: NCT02665364. |
|
Cuvinte-cheie systemic lupus erythematosus, treatment, vaccination |
|
|